<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Athamneh M</submitter><funding>AFM telethon</funding><funding>Deutsche Gesellschaft für Muskelkranke</funding><funding>European Regional Development Fund</funding><pagination>e18122</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11037410</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(8)</volume><pubmed_abstract>Bi-allelic variants in VWA1, encoding Von Willebrand Factor A domain containing 1 protein localized to the extracellular matrix (ECM), were linked to a neuromuscular disorder with manifestation in child- or adulthood. Clinical findings indicate a neuromyopathy presenting with muscle weakness. Given that pathophysiological processes are still incompletely understood, and biomarkers are still missing, we aimed to identify blood biomarkers of pathophysiological relevance: white blood cells (WBC) and plasma derived from six VWA1-patients were investigated by proteomics. Four proteins, BET1, HNRNPDL, NEFM and PHGDH, known to be involved in neurological diseases and dysregulated in WBC were further validated by muscle-immunostainings unravelling HNRNPDL as a protein showing differences between V</pubmed_abstract><journal>Journal of cellular and molecular medicine</journal><pubmed_title>Proteomic studies in VWA1-related neuromyopathy allowed new pathophysiological insights and the definition of blood biomarkers.</pubmed_title><pmcid>PMC11037410</pmcid><funding_grant_id>21644</funding_grant_id><funding_grant_id>LiBi‐NME</funding_grant_id><funding_grant_id>LiBi-NME</funding_grant_id><funding_grant_id>NME‐GPS</funding_grant_id><funding_grant_id>NME-GPS</funding_grant_id><pubmed_authors>Athamneh M</pubmed_authors><pubmed_authors>Gangfuss A</pubmed_authors><pubmed_authors>Sickmann A</pubmed_authors><pubmed_authors>Daya N</pubmed_authors><pubmed_authors>Marina AD</pubmed_authors><pubmed_authors>Schara-Schmidt U</pubmed_authors><pubmed_authors>Guttsches AK</pubmed_authors><pubmed_authors>Ruck T</pubmed_authors><pubmed_authors>Preusse C</pubmed_authors><pubmed_authors>Vorgerd M</pubmed_authors><pubmed_authors>Hentschel A</pubmed_authors><pubmed_authors>Deschauer M</pubmed_authors><pubmed_authors>Roos A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Proteomic studies in VWA1-related neuromyopathy allowed new pathophysiological insights and the definition of blood biomarkers.</name><description>Bi-allelic variants in VWA1, encoding Von Willebrand Factor A domain containing 1 protein localized to the extracellular matrix (ECM), were linked to a neuromuscular disorder with manifestation in child- or adulthood. Clinical findings indicate a neuromyopathy presenting with muscle weakness. Given that pathophysiological processes are still incompletely understood, and biomarkers are still missing, we aimed to identify blood biomarkers of pathophysiological relevance: white blood cells (WBC) and plasma derived from six VWA1-patients were investigated by proteomics. Four proteins, BET1, HNRNPDL, NEFM and PHGDH, known to be involved in neurological diseases and dysregulated in WBC were further validated by muscle-immunostainings unravelling HNRNPDL as a protein showing differences between V</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-04-22T03:28:38.745Z</modification><creation>2026-04-22T03:13:29.043Z</creation></dates><accession>S-EPMC11037410</accession><cross_references><pubmed>38652110</pubmed><doi>10.1111/jcmm.18122</doi></cross_references></HashMap>